Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HARMONY BIOSCIENCES HOLDINGS, INC.

(HRMY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2021 10/13/2021 10/14/2021 10/15/2021 10/18/2021 Date
36.02(c) 37.19(c) 38.44(c) 39.4(c) 38.731 Last
247 620 240 002 139 446 324 156 893 Volume
+1.95% +3.25% +3.36% +2.50% -1.70% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 307 M - -
Net income 2021 67,0 M - -
Net Debt 2021 29,9 M - -
P/E ratio 2021 34,9x
Yield 2021 -
Sales 2022 503 M - -
Net income 2022 173 M - -
Net cash position 2022 97,0 M - -
P/E ratio 2022 13,8x
Yield 2022 -
Capitalization 2 246 M 2 246 M -
EV / Sales 2021 7,41x
EV / Sales 2022 4,27x
Nbr of Employees 150
Free-Float 79,5%
More Financials
Company
Harmony Biosciences Holdings, Inc. is a holding company. The Company through its subsidiary, Harmony Biosciences, LLC., operates as a pharmaceutical company, which is focused on therapies for patients suffering from central nervous system disorders. It provides treatment options for people living with rare and orphan diseases, with an emphasis on central nervous system disorders, patients living with narcolepsy. It... 
Sector
Pharmaceuticals
Calendar
11/16Presentation
More about the company
Ratings of Harmony Biosciences Holdings, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about HARMONY BIOSCIENCES HOLDINGS, INC.
09/23HARMONY BIOSCIENCES : Needham Starts Harmony Biosciences Holdings at Buy With $57 Price Ta..
MT
09/22HARMONY BIOSCIENCES : Announces winners of patients at the heart and progress at the heart..
PU
09/20HARMONY BIOSCIENCES HOLDINGS, INC.(N : HRMY) added to S&P TMI Index
CI
09/03INSIDER SELL : Harmony Biosciences Holdings
MT
09/02HARMONY BIOSCIENCES : Drug Gets American Academy Of Sleep Medicine's Recommendation for Tr..
MT
09/02HARMONY BIOSCIENCES : Announces inclusion of wakix® (pitolisant) in american academy of sl..
PU
09/02Harmony Biosciences Announces Inclusion Of WAKIX® In American Academy Of Sleep Medicine..
CI
09/02HARMONY BIOSCIENCES : To Participate In Three Investor Conferences In September
PR
08/11HARMONY BIOSCIENCES : Transcript of Conference Call held by the Company on August 10, 2021..
PU
08/11Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Second Half of 202..
CI
08/11HARMONY BIOSCIENCES HOLDINGS, INC. : Results of Operations and Financial Condition, Regula..
AQ
08/10UPDATE : Harmony Biosciences Shares Jump After Q2 Gains Surprise, Blackstone Agrees to Pro..
MT
08/10HARMONY BIOSCIENCES : Swings to Q2 Profit as Revenue Surges
MT
08/10HARMONY BIOSCIENCES : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
08/10HARMONY BIOSCIENCES : HRMY Q2 2021BusinessUpdate-FINAL.pdf
PU
More news
News in other languages on HARMONY BIOSCIENCES HOLDINGS, INC.
09/02Un médicament de Harmony Biosciences est recommandé par l'American Academy of Sleep Med..
05/07HBM boucle l'exercice 2020 sur un bénéfice net record
05/07EQS-ADHOC : HBM Healthcare Investments erzielt im Geschäftsjahr 2020/2021 einen Jahresgewi..
More news
Analyst Recommendations on HARMONY BIOSCIENCES HOLDINGS, INC.
More recommendations
Chart HARMONY BIOSCIENCES HOLDINGS, INC.
Duration : Period :
Harmony Biosciences Holdings, Inc. Technical Analysis Chart | HRMY | US4131971040 | MarketScreener
Technical analysis trends HARMONY BIOSCIENCES HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 39,40 $
Average target price 52,75 $
Spread / Average Target 33,9%
EPS Revisions
Managers and Directors
John C.s Jacobs President, Chief Executive Officer & Director
Sandipkumar S. Kapadia Chief Financial Officer
Jeffrey S. Aronin Non-Executive Chairman
Jeffrey M. Dayno Chief Medical Officer
David Bradshaw Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
HARMONY BIOSCIENCES HOLDINGS, INC.8.99%2 246
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657